scholarly journals Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study

2011 ◽  
Vol 105 (7) ◽  
pp. 881-883 ◽  
Author(s):  
R Erichsen ◽  
C F Christiansen ◽  
T Frøslev ◽  
J Jacobsen ◽  
H T Sørensen
Keyword(s):  
Atrial Fibrillation ◽  
Cohort Study ◽  
Cancer Patients ◽  
Bisphosphonate Therapy ◽  
Intravenous Bisphosphonate

scholarly journals Intravenous bisphosphonate therapy does not thicken cementum or change periodontal ligaments of cancer patients

2017 ◽  
Vol 123 (5) ◽  
pp. 591-599 ◽  
Author(s):  
Mariana de Pauli Paglioni ◽  
Wagner Gomes Silva ◽  
Juliana Pereira ◽  
César Augusto Migliorati ◽  
Marcio Ajudarte Lopes ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Bisphosphonate Therapy ◽  
Intravenous Bisphosphonate ◽  
Periodontal Ligaments

scholarly journals Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study

2020 ◽  
Vol 11 (1) ◽  
pp. 92-99 ◽  
Author(s):  
Victor Chien-Chia Wu ◽  
Chun-Li Wang ◽  
Yu-Tung Huang ◽  
Wen-Ching Lan ◽  
Michael Wu ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Cohort Study ◽  
Cancer Patients ◽  
Oral Anticoagulant ◽  
Population Based ◽  
Novel Oral Anticoagulant

scholarly journals Atrial Fibrillation and Stroke Associated With Intravenous Bisphosphonate Therapy in Older Patients With Cancer

2010 ◽  
Vol 28 (33) ◽  
pp. 4898-4905 ◽  
Author(s):  
Gregg S. Wilkinson ◽  
Jacques Baillargeon ◽  
Yong-Fang Kuo ◽  
Jean L. Freeman ◽  
James S. Goodwin
Keyword(s):  
Atrial Fibrillation ◽  
Older Patients ◽  
Subsequent Development ◽  
Bisphosphonate Therapy ◽  
Cancer Type ◽  
Health Maintenance ◽  
Patients With Cancer ◽  
Increased Risk ◽  
Intravenous Bisphosphonate ◽  
Intravenous Bisphosphonates

Purpose Recent studies have linked the use of intravenous and orally administered bisphosphonates with subsequent development of atrial fibrillation. Patients with cancer who receive intravenous bisphosphonate therapy may be at particular risk for this adverse event because they receive higher doses of these drugs than do patients treated for other indications. We examined the association of intravenous bisphosphonates with atrial fibrillation, all classifications of supraventricular tachycardia (SVT), and stroke among older patients with cancer. Patients and Methods Using Surveillance, Epidemiology, and End Results (SEER) -Medicare–linked data, we identified older (≥ age 65 years) patients with cancer who were treated with intravenous infusions of bisphosphonates between January 1, 1995 and December 31, 2003. We then matched 13,714 bisphosphonate nonusers to 6,857 bisphosphonate users, at a 2:1 ratio, on cancer type, age, sex, presence of bone metastases, and SEER geographic region. Patients were observed until December 31, 2003 or until they lost coverage from Medicare Parts A and B; enrolled in a health maintenance organization; received a diagnosis of atrial fibrillation, any SVT, or stroke; or died. Results Receipt of intravenous bisphosphonates was modestly associated with an increased risk for atrial fibrillation (hazard ratio [HR] = 1.30; 95% CI, 1.18 to 1.43), all SVT (HR = 1.28; 95% CI, 1.19 to 1.38), and stroke (HR = 1.30; 95% CI, 1.09 to 1.54). The risk for all SVT increased 7% for each increase of five bisphosphonate dose equivalents (HR = 1.07; 95% CI, 1.02 to 1.12). Conclusion Clinicians who treat patients with cancer who have received intravenous bisphosphonates should be aware of the possible cardiovascular adverse events associated with this treatment.

Sign in / Sign up

Export Citation Format

Share Document